KRAS and neoplasm: In the subset of patients whose tumor harbored a KRAS G12C mutation (N = 30, 37% of all KRAS tumors), encouraging outcomes were also observed for the addition of ICI to chemotherapy with a PFS HR of 0.51 (95% CI: 0.21–1.21; p = 0.120) and an OS HR of 0.56 (95% CI: 0.20–1.56; p = 0.264) (Fig. 3C and D).